Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of daratumumab subcutaneous (SC) formulation for newly diagnosed multiple myeloma (NDMM), which would make it the only anti-CD38 therapy available for all patient types in the frontline setting [1][2][5]. Group 1: Company Developments - Janssen-Cilag International NV, a Johnson & Johnson company, announced the CHMP's positive recommendation for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone for adult patients with NDMM [1][5]. - The recommendation is based on the results from the Phase 3 CEPHEUS study, which demonstrated improved progression-free survival for patients receiving daratumumab-VRd compared to standard VRd [1][2][5]. - Daratumumab has been a foundational therapy in multiple myeloma treatment, with over 618,000 patients treated globally since its launch [5][6]. Group 2: Study Insights - The CEPHEUS study (NCT03652064) is an international, randomized, open-label Phase 3 trial that enrolled 395 patients with NDMM who were ineligible for stem cell transplantation [2][5]. - The primary endpoint of the study was the overall Minimal Residual Disease (MRD) negativity rate, with a median patient age of 70 years [2][5]. - Results from the CEPHEUS study were presented at the 2024 International Myeloma Society Annual Meeting and the 2024 American Society of Hematology Annual Meeting [1][2]. Group 3: Product Information - Daratumumab is the only CD38-directed antibody approved for subcutaneous administration in multiple myeloma treatment [5][6]. - The drug works by binding to CD38, a surface protein present on myeloma cells, inhibiting tumor cell growth and causing myeloma cell death [5][6]. - Data from ten Phase 3 clinical trials have shown significant improvements in progression-free survival and/or overall survival with daratumumab-based regimens [5][6].

Financial Data and Key Metrics Changes - Total revenue exceeded $1 billion for the first time, growing 22% year-over-year to $1.15 billion in 2024 [7][54] - Royalty revenue grew 27% to $571 million, contributing significantly to total revenue [10][54] - Net income increased 58% year-over-year to $444 million [10] - Adjusted EBITDA rose 48% to $632 million from $426 million in 2023 [55] - Non-GAAP diluted EPS increased to $4.23 from $2.77 in 2023 [56] Business Line Data and Key Metrics Changes - DARZALEX subcutaneous sales represented 95% of total DARZALEX sales in the U.S., with worldwide sales growing almost 24% to $3.1 billion in Q4 2024 [12][13] - Phesgo revenue reached approximately $2 billion for full year 2024, growing 72% year-over-year [16] - VYVGART and VYVGART Hytrulo sales reached $737 million in Q4 2024, with full year revenue of $2.2 billion [18] Market Data and Key Metrics Changes - The U.S. market for DARZALEX is projected to grow significantly, with analyst projections estimating over $17 billion in total revenue by 2028 [14] - Phesgo is expected to reach $3.4 billion in revenue by 2028 [17] - Ocrevus Zunovo sales reached approximately $7.7 billion in 2024, with significant growth opportunities anticipated [29] Company Strategy and Development Direction - The company aims to maintain strong revenue growth through existing products and new approvals, with a focus on expanding the ENHANZE platform [9][64] - The strategy includes extending patent protections and securing new partnerships to enhance revenue streams [9][44] - The company is actively pursuing new nominations and deals to drive future growth [45][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another record year in 2025, projecting total revenue growth of 13% to 21% [11][57] - The company anticipates continued strong growth from DARZALEX, Phesgo, and VYVGART Hytrulo, with VYVGART expected to be the largest growth driver in 2025 [11][57] - Management highlighted the importance of new product approvals and ongoing partnerships in sustaining long-term growth [64] Other Important Information - The company maintained a strong balance sheet with cash and marketable securities totaling $596 million as of December 31, 2024 [52] - A $250 million accelerated share repurchase program was initiated, with a total of $1.55 billion returned in share repurchases since 2019 [60][62] Q&A Session Summary Question: What is the confidence around new uses and argenx-related programs beyond 2028? - Management indicated high confidence in existing products continuing to contribute significantly post-2028, with multiple opportunities for new nominations and pipeline products [70][72] Question: Can you elaborate on the small-volume auto-injector's impact on partnerships? - Management explained that the small-volume auto-injector deal will create new revenue streams through development and commercial agreements, enhancing existing partnerships [80][82] Question: What are the dynamics behind the expected decrease in royalties for Q1? - Management clarified that annual rate resets and seasonality in certain products, particularly DARZALEX, contribute to the expected decrease in royalties for the first quarter [91][93] Question: How is the pre-filled syringe transition being incorporated into guidance? - Management confirmed that the guidance reflects the potential increase from the pre-filled syringe, which is expected to enhance patient access and adoption [98] Question: Will VYVGART subcutaneous sales exceed IV sales in 2025? - Management expressed excitement about the growth of VYVGART but refrained from commenting on specific timelines for when subcutaneous sales might exceed IV sales [113] Question: Are the three undisclosed products on Slide 23 new deals expected this year? - Management clarified that the three products are from current partners, with new deals expected to be over and above these nominations [115]